Voyager and Exobiosphere Will Expand ISS Research
The two firms will add two microgravity biotechnology campaigns starting in June 2027.
Updated on Sept. 24, 2026 in Biotech
Live Poll
Do you believe pharmaceutical companies should invest in drug research conducted on orbital space platforms?
Voyager Technologies and Exobiosphere have announced a plan to execute two additional research campaigns aboard the International Space Station. These research missions aim to establish a recurring, schedulable service for commercial biotech investigations in microgravity.
Why it matters
These planned campaigns represent a shift toward making space-based biotechnology a standardized, repeatable service rather than a series of one-off experiments. By utilizing specialized automation, the initiative seeks to lower the barrier for commercial drug discovery in low Earth orbit.
The Exobiosphere OHTS platform conducts automated drug screening on standardized well plates, allowing for the exchange of samples and test compounds between campaigns. This hardware setup is designed to adapt the station's capabilities to support new scientific investigations in real-time.
The players
Voyager Technologies
An aerospace company that develops space infrastructure and manages mission-critical payloads for orbit.
Exobiosphere
A biotechnology firm that creates automated, microgravity-compatible platforms for drug screening.
The details
The OHTS platform functions by automating the handling of test compounds and biological consumables in a microgravity environment. Voyager Space Solutions manages the payload processing and pre-flight preparations at a Houston facility, while Voyager Europe oversees mission management and integration. This coordinated process allows for the system to swap out samples between flights to facilitate continuous, iterative testing.
Timeline
April 2027: Installation of the OHTS platform on the International Space Station.
June 2027: Launch of the first research campaign.
August-September 2027: Launch of the second research campaign.
The Tech Race
This effort marks a progression from experimental space flight to the commercialization of the ISS National Laboratory for recurring pharmaceutical testing. It competes with other orbital biotech initiatives aiming to turn microgravity into a high-throughput, industrial-scale laboratory environment.
Commercial researchers in the pharmaceutical industry will gain access to a standardized platform for testing drugs in microgravity beginning in 2027. This workflow replaces bespoke, single-use experiments with a repeatable service model that allows for sample exchange between missions.
The takeaway
The transition to schedulable research campaigns signals the maturation of the space-based drug discovery sector. Stakeholders should monitor the successful installation of the OHTS platform in April 2027 as the primary milestone for this operational model.
Further reading
For broader context on current orbital research, explore our Biotech section.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you believe pharmaceutical companies should invest in drug research conducted on orbital space platforms?
